Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early C-peptide AUC measures in type 1 diabetes trials can predict long-term outcomes and support shorter studies. This dynamic assessment identifies treatment effects sooner, potentially reducing trial size and duration.
Area Of Science
- Immunology
- Endocrinology
- Clinical Trials
Background
- Type 1 diabetes (T1D) trials often use 12-24 month C-peptide AUC to assess β-cell preservation.
- Earlier detection of treatment efficacy could optimize trial design and resource allocation.
Purpose Of The Study
- To investigate if early dynamic measures of C-peptide AUC can predict long-term outcomes in T1D immunotherapy trials.
- To determine if shorter trial durations are feasible for establishing treatment efficacy.
Main Methods
- Post hoc analysis of six Type 1 Diabetes TrialNet immunotherapy trials.
- Examined dynamic C-peptide AUC changes at 3 and 6 months as predictors of 12-month outcomes.
- Partitioned trials into successful and unsuccessful based on primary endpoints.
Main Results
- A significant treatment effect was detected at 3 and 6 months using dynamic C-peptide AUC in successful trials (P = 0.030 and P < 0.001).
- Dynamic C-peptide AUC at 6 months strongly predicted 12-month C-peptide AUC preservation (R2 = 0.80, P < 0.001).
- This approach supported the feasibility of smaller trial sizes, down to 54 participants.
Conclusions
- Early dynamic C-peptide AUC measurements can identify treatment effects in successful T1D immunotherapy trials.
- These early markers offer good long-term predictive value and support shorter trial durations (6 months).
- External validation is needed, but findings support shortening early-phase clinical trials for T1D interventions.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...